	US 12,105,081 B2
	Treatment response assessment using normalized single cell measurements
Robert Kimmerling, Cambridge, MA (US); Selim Olcum, Cambridge, MA (US); and Mark Stevens, Cambridge, MA (US)
Assigned to Travera, Inc., Medford, MA (US)
Filed by Travera, Inc., Medford, MA (US)
Filed on Apr. 26, 2022, as Appl. No. 17/729,644.
Claims priority of provisional application 63/278,420, filed on Nov. 11, 2021.
Claims priority of provisional application 63/257,906, filed on Oct. 20, 2021.
Prior Publication US 2023/0119020 A1, Apr. 20, 2023
Int. Cl. G01N 33/50 (2006.01); B01L 3/00 (2006.01)

CPC G01N 33/5011 (2013.01) [B01L 3/502761 (2013.01); G01N 33/5032 (2013.01); B01L 2200/0652 (2013.01)]

20 Claims

1. A method for assessing cellular response to a treatment, the method comprising the steps of:

exposing a first portion of a biological sample comprising live cells to a treatment;

sequentially measuring a property of an untreated second portion, the first portion, and an untreated third portion of the sample;

normalizing the measurements of the first, second, and third portions with respect to the property;

establishing a baseline measurement as a difference between measured properties of the untreated second and third portions of the sample;

comparing the measured property of the first portion to the baseline; wherein a difference between the measured property of the first portion and the baseline is indicative of a cellular response to the treatment.